A parent of one of the initial infants worldwide to undergo treatment for a severe muscle degenerative ailment is endorsing a campaign calling for universal testing of all newborns for the condition. Portia Thorman, whose son Ezra was diagnosed with spinal muscular atrophy (SMA) as an infant, was informed that he would not survive beyond two years. Despite facing challenges with movement, speech, and breathing, Ezra, now nine years old, stands as a symbol of hope for parents of children grappling with the diagnosis, like singer Jesy Nelson.
Portia, aged 46 and residing in Ramsgate, emphasized the urgency of implementing newborn screening to enable early intervention before symptoms manifest, emphasizing that SMA is no longer a fatal prognosis. SMA type 1, the most severe variant of the disease, results from nerve cell degeneration in the brain and spinal cord soon after birth, impeding the transmission of messages that govern muscle function, leading to severe movement restrictions and respiratory and swallowing complications.
The Mirror has been advocating for the inclusion of SMA in the NHS newborn heel prick test, a move already adopted in many other developed nations. The campaign aims to prevent unnecessary paralysis in children. Jesy Nelson recently made headlines following the diagnosis of her twins, who will face mobility challenges due to late detection of SMA.
Expressing solidarity with Jesy, Portia acknowledged the initial shock and grief upon learning about the diagnosis but emphasized finding joy and taking each day as it comes in caring for such children. Pharmaceutical company Novartis estimates that 33 babies in the UK annually end up needing a wheelchair due to delayed diagnoses, highlighting the critical need for early detection measures.
Ezra’s journey, marked by numerous health setbacks in his early years, underscores the importance of timely intervention. Despite the grim initial prognosis, the advent of Nusinersen, a groundbreaking treatment administered to Ezra, has demonstrated promising outcomes. The drug, also known as Spinraza, boosts the production of a crucial motor neuron protein, offering hope for improved quality of life.
While significant advancements have been made in SMA treatments, delayed diagnoses remain a concern, leading to irreversible nerve damage and disabilities. The UK’s lag in SMA screening contrasts starkly with other nations, with calls for prompt action to align with global standards. The UK National Screening Committee’s cautious approach in implementing SMA screening prompts concerns about missed opportunities for early intervention.
Portia’s family’s ordeal exemplifies the profound impact of SMA and the transformative potential of early detection and treatment. Emphasizing the need for nationwide screening to avert unnecessary suffering, Portia advocates for a comprehensive approach across England, Wales, and Northern Ireland to ensure equitable access to preventive measures for all newborns.
By prioritizing early screening and intervention, the healthcare system can mitigate the devastating effects of SMA, offering affected children a chance at a better quality of life.